Standout Papers

Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial 2021 2026 2022 2024238
  1. Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial (2021)
    Stephen A. Harrison, Peter Ruane et al. Nature Medicine

Immediate Impact

5 by Nobel laureates 1 from Science/Nature 60 standout
Sub-graph 1 of 22

Citing Papers

A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
2024 Standout
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
2024 Standout
1 intermediate paper

Works of B. Freilich being referenced

Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
2021 Standout
CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients
2019

Author Peers

Author Last Decade Papers Cites
B. Freilich 450 723 30 289 32 1.0k
Brian B. Borg 504 817 57 179 30 1.2k
Marlene Kohlhepp 545 752 15 255 22 1.3k
Gillian Patman 433 733 23 194 42 998
Sadataka Inuzuka 515 658 17 262 36 1.2k
Saiyu Tanaka 337 720 9 343 42 1.2k
Shinya Nagaoka 713 829 62 116 29 1.1k
Yasushi Seo 369 454 21 256 43 1.1k
Zhaolian Bian 474 624 75 439 58 1.4k
Mar Coll 740 671 13 370 35 1.4k
Naoaki Akisawa 237 586 46 340 21 1.0k

All Works

Loading papers...

Rankless by CCL
2026